Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility

BACKGROUND AND OBJECTIVES: Imipenem/relebactam (IMP/R) is a newly FDA approved β-lactam/β-lactamase inhibitor combination. Relebactam ability to restore IMP activity could differ according to the cause of imipenem non-susceptibility. Therefore, we investigated the in-vitro activity of IMP/R against...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashaly, Mervat El-Sayed, Mashaly, Ghada El-Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816701/
https://www.ncbi.nlm.nih.gov/pubmed/35222856
http://dx.doi.org/10.18502/ijm.v13i6.8080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816701/
https://www.ncbi.nlm.nih.gov/pubmed/35222856
http://dx.doi.org/10.18502/ijm.v13i6.8080

Ejemplares similares